1. Search Result
Search Result
Results for "

glucose kinase

" in MedChemExpress (MCE) Product Catalog:

36

Inhibitors & Agonists

2

Screening Libraries

1

Biochemical Assay Reagents

4

Peptides

10

Natural
Products

1

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W145521
    β-1,3-Glucan
    1 Publications Verification

    β Glucan

    Biochemical Assay Reagents IKK NO Synthase Bacterial Infection Inflammation/Immunology Cancer
    β-1,3-Glucan (β Glucan) is an orally active polysaccharide composed of glucose polymers. β-1,3-Glucan increase the activity of IKKβ kinase, enhances the production of nitric oxide. β-1,3-Glucan improves resistance to Vibrio harveyi infection. β-1,3-Glucan enhances immune response, promotes blood pressure recovery, reduces lung, kidney and liver damage, inhibits the growth of syngeneic tumors .
    β-1,3-Glucan
  • HY-126585
    SAICAR
    4 Publications Verification

    Endogenous Metabolite Cancer
    SAICAR is an intermediate of de novo purine nucleotide biosynthesis, activates pyruvate kinase isoform M2 (PKM2) in an isozyme-selective manner, with an EC50 of 0.3 mM. SAICAR stimulates PKM2 and promotes cancer cell survival in glucose-limited conditions .
    SAICAR
  • HY-128574

    DS11252927

    GLUT PI3K Akt Metabolic Disease
    D927 (DS11252927) is an orally active glucose transporter type 4 (GLUT4) translocation activator with an EC50 of 0.14 μM. D927 enhances the binding affinity of PI3Kα catalytic subunit p110α to canonical RAS proteins (KRAS4A, KRAS4B) and RRAS, RRAS2, MRAS. D927 activates the PI3Kα-AKT pathway (increasing phosphorylation of AKT, p70S6 kinase) without affecting the RAF-ERK1/2 pathway. D927 improves hyperglycemia in type 1 and type 2 diabetes mice model. D927 can be used for the study of glucose homeostasis disorders and diabetes .
    D927
  • HY-15589
    GW9508
    5+ Cited Publications

    Free Fatty Acid Receptor Potassium Channel Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC50s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (KATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities .
    GW9508
  • HY-B0481
    Miglitol
    2 Publications Verification

    BAY1099; BAY-m1099

    Glycosidase AMPK Reactive Oxygen Species (ROS) Metabolic Disease
    Miglitol (BAY-m1099) is an orally active antidiabetic compound that inhibits the breakdown of glycoconjugates into glucose. Miglitol inhibits glycoside hydrolase enzymes called α-glucosidases. Miglitol inhibits oxidative stress-induced apoptosis and mitochondrial ROS over-production in endothelial cells by enhancement of AMP-activated protein kinase. Dietary supplementation with Miglitol from pre-onset stage in OLETF rats delays the onset and development of diabetes and preserves the insulin secretory function of pancreatic islets .
    Miglitol
  • HY-P2917

    GyK

    Nuclear Hormone Receptor 4A/NR4A Metabolic Disease Inflammation/Immunology
    Glycerol kinase, microorganism (GyK) acts as a NR4A1 inhibitor with enzymatic activity. It directly binds to and inhibits the transcription factor NR4A1, thereby negatively regulating hepatic gluconeogenesis and reducing blood glucose levels. Glycerol kinase, microorganism positively regulates UCP1 expression via partial dependence on the β-adrenergic receptor-cAMP-CREB pathway, promotes browning of white adipose tissue and thermogenesis, and further modulates intracellular fatty acid composition and energy metabolism. In diabetic mouse models, overexpression of Glycerol kinase effectively antagonizes NR4A1-induced hyperglycemia, demonstrating potential for improving glucose homeostasis. Glycerol kinase, microorganism can be used for studies on diabetes and obesity .
    Glycerol kinase, microorganism
  • HY-148189
    Aldometanib
    Maximum Cited Publications
    9 Publications Verification

    LXY-05-029

    Fructose-1,6-bisphosphate aldolase AMPK Metabolic Disease
    Aldometanib (LXY-05-029) is an orally active aldolase inhibitor. Aldometanib can activate lysosomal adenosine monophosphate-activated protein kinase (AMPK) and decreases blood glucose. Aldometanib can be used for the research of metabolic homeostasis .
    Aldometanib
  • HY-P1856
    Proinsulin C-peptide (human)
    1 Publications Verification

    Insulin Receptor PDGFR MAPKAPK2 (MK2) Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Proinsulin C-peptide (human) is a peptide consisting of 31 amino acids that links the A and B chains of proinsulin to ensure its correct folding. Proinsulin C-peptide (human) inhibits the high glucose-induced increase in PDGF-β receptor protein expression and the phosphorylation of p42/p44 MAP kinase. Proinsulin C-peptide (human) increases the deformability of erythrocytes derived from type 1 diabetes, inhibits insulin-induced neointimal thickening, and suppresses the proliferation of rat aortic smooth muscle cells cultured under high-glucose conditions .
    Proinsulin C-peptide (human)
  • HY-N0712
    Typhaneoside
    3 Publications Verification

    Autophagy mTOR Akt FXR Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Typhaneoside is an orally bioavailable signal modulator and cellular regulator. Typhaneoside regulates the PI3K/Akt/mTOR autophagy transduction pathway. Typhaneoside promotes the activation of AMP-activated protein kinase and Caspase-3, induces apoptosis, ferroptosis, autophagy, ROS accumulation, and cell cycle arrest at the G2/M phase, and reduces cancer cell viability. Typhaneoside activates the farnesoid X receptor signaling pathway, improves glucose and lipid metabolism, alleviates inflammatory responses, oxidative stress and hepatic lipid accumulation, and exerts hepatoprotective effects. Typhaneoside is applicable to research related to post-myocardial infarction heart failure, acute myeloid leukemia, non-alcoholic fatty liver disease, and neurological disorders .
    Typhaneoside
  • HY-121744
    PS10
    5+ Cited Publications

    PDHK Inflammation/Immunology
    PS10 is a novel, potent and ATP-competitive pan-PDK inhibitor, inhibits all PDK isoforms with IC50 of 0.8 μM, 0.76 μM, 2.1 μM and 21.3 μM for PDK2, PDK4, PDK1, and PDK3, respectively. PS10 shows high affinity for PDK2 (Kd= 239 nM) than for Hsp90 (Kd= 47 μM) . PS10 improves glucose tolerance, stimulates myocardial carbohydrate oxidation in diet-induced obesity. PS10 has the potential for the investigation of diabetic cardiomyopathy .PDK: pyruvate dehydrogenase kinase
    PS10
  • HY-N0419
    Quercimeritrin
    2 Publications Verification

    Quercetin-7-O-β-D-glucopyranoside

    Glycosidase c-Kit MMP VEGFR Aurora Kinase Metabolic Disease Cancer
    Quercimeritrin (Quercetin-7-O-β-D-glucopyranoside) is an orally active α-glucosidase inhibitor (with an IC50 of 79.88 μM against the Saccharomyces cerevisiae enzyme) and a P-gp substrate, with anti-angiogenic and antioxidant activities. Quercimeritrin does not cross the blood-brain barrier and does not inhibit cytochrome P450 enzymes. Quercimeritrin precisely binds to and inhibits the active sites of c-Kit, MMP-2, Aurora-A kinases and α-glucosidase, thereby disrupting target functions. Quercimeritrin effectively regulates postprandial blood glucose and also exhibits significant anti-angiogenic activity, which inhibits endothelial cell proliferation and microvascular growth. Quercimeritrin can be used in the research of diabetes and breast cancer .
    Quercimeritrin
  • HY-N6258
    Kahweol
    1 Publications Verification

    AMPK Apoptosis Metabolic Disease Cancer
    Kahweol is one of the consituents of the coffee from Coffea Arabica with anti-inflammatory anti-angiogenic, and anti-cancerous activities. Kahweol inhibits adipogenesis and increase glucose uptake by AMP-activated protein kinase (AMPK) activation. Kahweol induces apoptosis.
    Kahweol
  • HY-N7515

    2',4',6'-Trihydroxychalcone

    Bacterial AMPK Infection Metabolic Disease Inflammation/Immunology
    Pinocembrin chalcone (2',4',6'-Trihydroxychalcone) is an antibacterial compound from Helichrysum Trilineatum. Pinocembrin chalcone facilitates AMP-activated protein kinase (AMPK) activation, improves glucose tolerance, increases muscle FAO and reduces fat accumulation in the liver and skeletal muscles in high-fat diet-induced (HFD) diabetic mice. Pinocembrin chalcone is promising for research of gastric ulcers and diabetes .
    Pinocembrin chalcone
  • HY-E70032

    Endogenous Metabolite Metabolic Disease
    N-Acetylhexosamine kinase (NahK) is an anomeric kinase acting on a glucose-type substrate. N-Acetylhexosamine kinase catalyzes the phosphorylation of GlcNAc or GalNAc at the anomeric C1 position with ATP to form N-acetylhexosamine 1-phosphate (GlcNAc-1P/GalNAc-1P) .
    N-Acetylhexosamine kinase (NahK)
  • HY-W005629

    Environmental Pollutants Cannabinoid Receptor PDK-1 Metabolic Disease Cancer
    Leelamine is an orally active pyruvate dehydrogenase kinase (PDK) inhibitor with an IC50 value of 9.5 μM, showing a blood glucose lowering effect in the diabetic mouse. Leelamine is also a weak agonist of cannabinoid receptors CB1 and CB2. Leelamine decreases mitotic activity, prostate-specific antigen expression and induces Apoptosis to cell death in cancer cells .
    Leelamine
  • HY-128578
    KPLH1130
    2 Publications Verification

    PDHK NO Synthase Interleukin Related HIF/HIF Prolyl-Hydroxylase Metabolic Disease Inflammation/Immunology
    KPLH1130 is a pyruvate dehydrogenase kinase (PDK) inhibitor. KPLH1130 potently inhibits M1 macrophage polarization by reducing the expression of pro-inflammatory cytokines, decreasing the levels of M1 phenotype markers (HIF-1α, iNOS) and nitric oxide (NO) production. KPLH1130 prevents the reduction of mitochondrial oxygen consumption rate (OCR) induced by inflammatory stimuli (LPS ((HY-D1056) + IFN-γ) in various macrophage types. KPLH1130 improves glucose tolerance in HFD-fed mice. KPLH1130 can be used for the study of obesity-associated metabolic disorders and other inflammatory conditions .
    KPLH1130
  • HY-155157

    Endogenous Metabolite Cardiovascular Disease
    PF-07247685 is a BCKDC kinase (BDK) inhibitor (EC50=2.2 nM). PF-07247685 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07247685 improved cardiometabolic endpoints and improves glucose tolerance in mice .
    PF-07247685
  • HY-131940

    3-O-Methyl-GlcNAc

    Insecticide Metabolic Disease
    3-O-Methyl-N-acetyl-D-glucosamine is a potent inhibitor of N-acetylglucosamine kinase. 3-O-Methyl-N-acetyl-D-glucosamine potently inhibits glucose phosphorylation by N-acetylglucosamine kinase whereas glucokinase is not at all affected by this hexosamine .
    3-O-Methyl-N-acetyl-D-glucosamine
  • HY-N6841
    Rhodiolin
    1 Publications Verification

    Glucose-6-Phosphate Isomerase (GPI) Casein Kinase Virus Protease Flavivirus PI3K Akt mTOR Apoptosis Infection Cancer
    Rhodiolin, a flavonoid, is an orally active glucose 6-phosphate isomerase (GPI) inhibitor. Rhodiolin inhibits papillary thyroid cancer (PTC) by targeting glycolysis enzyme glucose 6-phosphate isomerase GPI and suppressing PI3K/AKT/mTOR phosphorylation and induce apoptosis. Rhodiolin as a NS2B-NS3 protease inhibitor can disrupt dengue viral replication. Rhodiolin is also a potential candidate for developing anticancer strategies inhibiting CK1ε kinase. Rhodiolin can be used for the study of anti-tumor and anti-viral .
    Rhodiolin
  • HY-N8540

    Phosphoglycerate Kinase (PGK) Fungal Apoptosis Infection Cancer
    Ilicicolin H is a selective and non-ATP-competitive phosphoglycerate kinase 1 (PGK1) (IC50 = 9.02 μM) and mitochondrial cytochrome bc1 reductase (IC50 = 2-3 ng/mL) inhibitor. Ilicicolin H directly binds to PGK1 with KD of 60 μM .Ilicicolin H can inhibit cell proliferation and induce apoptosis. Ilicicolin H can inhibit the lactate production and glucose uptake of hepatocellular carcinoma (HCC) cells. Ilicicolin H has a broad antifungal spectrum including C. albicans, Cryptococcus and A. fumigatus. Ilicicolin H can be used for the researches of cancer and infection, such as hepatocellular carcinoma (HCC) and C. albicans infection .
    Ilicicolin H
  • HY-125863A

    G6PD (Leuconostoc sp., recombinant)

    Endogenous Metabolite Metabolic Disease
    Glucose-6-phosphate dehydrogenase (Leuconostoc sp., recombinant) is an NADP-dependent enzyme in the pentose phosphate pathway, which is one of the ways glucose is metabolized. Glucose-6-phosphate dehydrogenase (Leuconostoc sp., recombinant) can be used to quantify ATP, glucose, and creatine kinase .
    Glucose-6-phosphate dehydrogenase (Leuconostoc sp., recombinant)
  • HY-126585S

    Endogenous Metabolite Metabolic Disease
    SAICAR-d3 is the deuterium labeled SAICAR. SAICAR is an intermediate of de novo purine nucleotide biosynthesis, activates pyruvate kinase isoform M2 (PKM2) in an isozyme-selective manner, with an EC50 of 0.3 mM. SAICAR stimulates PKM2 and promotes cancer cell survival in glucose-limited conditions .
    SAICAR-d3
  • HY-15589R

    Free Fatty Acid Receptor Potassium Channel Reference Standards Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    GW9508 (Standard) is the analytical standard of GW9508. This product is intended for research and analytical applications. GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC50s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (KATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities .
    GW9508 (Standard)
  • HY-P1401

    PKC Metabolic Disease
    Protein Kinase C (19-36) is a pseudosubstrate peptide inhibitor of protein kinase C (PKC), with an IC50 of 0.18 μM. Protein Kinase C (19-36) markedly attenuated vascular hyperproliferation and hypertrophy as well as glucose-induced suppression of natriuretic peptide receptor response .
    Protein Kinase C (19-36)
  • HY-155156

    Endogenous Metabolite Cardiovascular Disease
    PF-07238025 is a BCKDC kinase (BDK) inhibitor (EC50=19 nM). PF-07238025 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07238025 improved cardiometabolic endpoints and improves glucose tolerance in mice .
    PF-07238025
  • HY-P3257B

    ADP-Dependent hexokinase, thermococcus litoralis

    Glucokinase Neurological Disease Metabolic Disease Cancer
    ADP-Specific glucokinase, thermococcus litoralis is an ADP-specific glucose kinase expressed in thermophilic archaea. ADP-Specific glucokinase, thermococcus litoralis can catalyze glucose into glucose-6-phosphate, which promotes glycolysis. ADP-Specific glucokinase, thermococcus litoralis can activate T cells and enhance the phagocytic activity of macrophages. ADP-Specific glucokinase, thermococcus litoralis can be used in research on metabolic diseases, neurological disorders, and tumors .
    ADP-Specific glucokinase, thermococcus litoralis
  • HY-P3257A

    ADP-dependent hexokinase, pyrococcus furiosus

    Glucokinase Neurological Disease Metabolic Disease Cancer
    ADP-Specific glucokinase, pyrococcus furiosus is an ADP-specific glucose kinase expressed in thermophilic archaea. ADP-Specific glucokinase, pyrococcus furiosus can catalyze glucose into glucose-6-phosphate, which promotes glycolysis. ADP-Specific glucokinase, pyrococcus furiosus can activate T cells and enhance the phagocytic activity of macrophages. ADP-Specific glucokinase, pyrococcus furiosus can be used in research on metabolic diseases, neurological disorders, and tumors .
    ADP-specific glucokinase, pyrococcus furiosus
  • HY-P1873

    Ser/Thr Protease Endocrinology
    Phosphorylase Kinase β-Subunit Fragment (420-436) is the β-Subunit fragment (peptide 430-436) of phosphorylase kinase. Phosphorylase kinase is a serine/threonine-specific protein kinase which activates glycogen phosphorylase to release glucose-1-phosphate from glycogen .
    Phosphorylase Kinase β-Subunit Fragment (420-436)
  • HY-138842

    Insulin Receptor Akt ERK Metabolic Disease
    DDN is a selective insulin receptor (Insulin Receptor) activator, an insulin sensitizer, and a glucose-lowering insulin mimetic with oral bioavailability. DDN can directly bind to the receptor kinase domain and induce Akt and ERK phosphorylation, and it can also enhance insulin's effect on glucose uptake. DDN significantly reduces blood glucose levels in wild-type and diabetic ob/ob and db/db mice .
    DDN
  • HY-162586

    PDHK Cancer
    PDHK-IN-7 (compound 32) is an inhibitor of pyruvate dehydrogenase kinase with an IC50 value of 17 nM.PDHK-IN-7 activates PDH in rat livers and has a glucose-lowering effect in Zucker fatty rats .
    PDHK-IN-7
  • HY-N6258R

    Reference Standards AMPK Apoptosis Metabolic Disease
    Kahweol (Standard) is the analytical standard of Kahweol. This product is intended for research and analytical applications. Kahweol is one of the consituents of the coffee from Coffea Arabica with anti-inflammatory anti-angiogenic, and anti-cancerous activities. Kahweol inhibits adipogenesis and increase glucose uptake by AMP-activated protein kinase (AMPK) activation. Kahweol induces apoptosis.
    Kahweol (Standard)
  • HY-136631

    Glucokinase Metabolic Disease
    PF-04279405 is a potent and full-acting glucokinase (GK) agonist (EC50=23 nM). Glucokinase (GK) is an enzyme responsible for the conversion of glucose to glucose-6-phosphate and plays a key role in maintaining blood glucose homeostasis. PF-04279405 can be used in the research of type 2 diabetes .
    PF-04279405
  • HY-174687

    mRNA Cancer
    Human FGFR4 mRNA encodes the human fibroblast growth factor receptor 4 (FGFR4) protein, a tyrosine kinase and cell surface receptor for fibroblast growth factors. FGFR4 is involved in the regulation of several pathways, including cell proliferation, cell differentiation, cell migration, lipid metabolism, bile acid biosynthesis, vitamin D metabolism, glucose uptake, and phosphate homeostasis.
    Human FGFR4 mRNA
  • HY-P1873B

    Ser/Thr Protease Metabolic Disease
    Phosphorylase Kinase β-Subunit Fragment (420-436) acetate is the β-Subunit fragment (peptide 430-436) of phosphorylase kinase. Phosphorylase kinase is a serine/threonine-specific protein kinase which activates glycogen phosphorylase to release glucose-1-phosphate from glycogen .
    Phosphorylase Kinase β-Subunit Fragment (420-436) acetate
  • HY-E70994

    Biochemical Assay Reagents Metabolic Disease
    Fructose-6-phosphate Kinase, Bacillus stearothermophilus (EC 2.7.1.11) is an important enzyme in glucose metabolism. Fructose-6-phosphate Kinase, Bacillus stearothermophilus (EC 2.7.1.11) catalyzes the hydrolysis of fructose-1,6-bisphosphate to fructose-6-phosphate and inorganic phosphate.
    Fructose-6-phosphate Kinase, Bacillus stearothermophilus
  • HY-107387

    PI3K Metabolic Disease Inflammation/Immunology
    PF-376304 is an orally active non-specific class I phosphoinositide 3-kinase (PI3K) inhibitor with an IC50 of 0.197 μM against PI3Kγ. PF-376304 induces dose-dependent glucose and lipid metabolic disorders in rats, causes rapid death at high doses, and leads to metabolic abnormalities that are self-reversible at low doses. PF-376304 is applicable to the research of metabolic and inflammatory diseases .
    PF-376304

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: